Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Oncolytics Biotech Inc.NASDAQ: ONCY

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -CA$438.74M, compared with -CA$484.4M a year earlier.

Context

  • Retained earnings amounted to 5376.0% of total assets at the end of Q1 FY2026, up 2917.4 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +9.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$438.74M-2.2% QoQ
Last fiscal yearDec 2025
-CA$589.32M-23.4% YoY
Year agoMar 2025
-CA$484.4M+9.4% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.4%——
1 year-23.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

CAD · from the balance sheet

Latest · FY2025
(589.32M) CAD
Year-over-year change
-23.4%

Retained Earnings vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +9.4% is the highest of 9, against a peer median of -27.9%.
  • Retained earnings amounts to 5376.0% of total assets for ONCY, versus a peer median of 424.7%.
ONCY Competitors
Retained Earnings for ONCY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
COYACoya Therapeutics, Inc.Mar 2026-$69.17M USD-44.0%—129.8%
IMMXImmix Biopharma, Inc.Mar 2026-$114.55M USD-44.0%—119.6%
CLNNClene Inc.Mar 2026-$316.39M USD-11.8%—1460.4%
WHWKWhitehawk Therapeutics IncMar 2026-$375.44M USD-44.6%—295.1%
ONCYOncolytics Biotech Inc.Mar 2026-CA$438.74M CAD+9.4%—5376.0%
SRZNSurrozen, Inc.Mar 2026-$654.79M USD-109.7%—542.5%
TILInstil Bio, Inc.Mar 2026-$730.69M USD-6.9%—364.6%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026-$1.23B USD-11.3%—484.8%
MGNXMacroGenics, Inc.Mar 2026-$1.28B USD-5.8%—588.0%
Peer median (excluding ONCY) —-27.9%—424.7%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents41.26M11.67M34.91M15.94M7.14M
Short-term Investments020.47M000
Net Receivables866K521K15K68K786.23K
Inventory00000
Other Current Assets000980K0
Total Current Assets44.9M35.68M38.17M18.88M9.39M
Property, Plant & Equipment (Net)976K652K647K1.31M1.01M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0998K000
Total Non-current Assets976K1.65M647K1.31M1.01M
Total Assets45.88M37.33M38.82M20.19M10.4M
Account Payables594K2.25M1.08M1.09M4.81M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities408K79K532K1.62M3.3M
Total Current Liabilities2.69M3.95M4.24M6.69M8.37M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)6.73M6.73M6.73M6.73M6.74M
Other Non-current Liabilities00000
Total Non-current Liabilities7.09M6.89M7.02M7.52M7.24M
Total Liabilities9.78M10.83M11.26M14.2M15.62M
Common Stock391.35M404.04M430.91M438.19M0
Retained Earnings(393.42M)(418.25M)(446M)(477.71M)(589.32M)
Accumulated OCI388K662K544K961K8.54M
Other Stockholders Equity3.62M0000
Minority Interest00000
Total Equity36.1M26.5M27.56M5.98M(5.21M)
Total Debt655K373K423K1.06M772.51K
Net Debt(40.61M)(11.29M)(34.49M)(14.88M)(6.37M)

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.